HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Borghese

This article was originally published in The Rose Sheet

Executive Summary

Cura-C Vitamin C Eye Treatment, debuting in April, prevents the acceleration of premature aging by preserving, producing and repairing collagen, the firm says. The product joins the company's Cura-C Anhydrous Vitamin C Treatment (1"The Rose Sheet" Aug. 17, 1998, p. 3). With daily use of the eye cream, "dark circles, fine lines and signs of fatigue seem to disappear as elasticity is improved," Borghese claims. The product also contains borage seed oil and cyclomethicone to moisturize. A .5 oz. tube retails for $42.50
Advertisement

Related Content

Borghese Tightens Distribution To 500 Doors Under Management Redesign
Borghese Tightens Distribution To 500 Doors Under Management Redesign
Borghese Cura-C anhydrous vitamin C treatment in light- repellent jar to debut in October.
Borghese Cura-C anhydrous vitamin C treatment in light- repellent jar to debut in October.
Advertisement
UsernamePublicRestriction

Register

RS007644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel